Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) Muscle dysfunction Urinary titin Titin
Conditions
Interventions
Patients diagnosed with chronic obstructive pulmonary disease (COPD) according to the 2024 GOLD COPD guidelines, with a post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital cap
Screening,Screening
COPD,Control
Sponsors
Research department
Eligibility
Sex/Gender
Male
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: COPD group 1. Patients diagnosed with chronic obstructive pulmonary disease (COPD) according to the 2024 GOLD COPD guidelines, with a post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio less than 0.7. 2. Aged between 40 and 80 years. 3. Able to communicate and follow instructions. 4. No exacerbations within 4 weeks prior to the test date. Control group 1. Pulmonary function test results are normal, with an FEV1/FVC ratio greater than or equal to 0.7. 2. Aged between 60 and 80 years*. 3. Able to communicate and follow instructions. 4. No history of smoking. 5. Normal chest X-ray. 6. No signs of malnutrition. 7. No lung diseases, such as asthma, pulmonary fibrosis, or emphysema. 8. No other diseases affecting muscle strength and mass testing, or titin levels, such as cancer, kidney disease, or cardiovascular disease.
Exclusion criteria
Exclusion criteria: 1. History of lower and/or upper limb amputation. 2. Muscle injury sustained within 1 month prior to participation in the study. 3. Surgery resulting in muscle injury within 6 months before participating in the study. 4. Acute kidney failure or chronic kidney disease stage 3 or higher, or receiving kidney replacement therapy. 5. Diagnosed with a neuromuscular disease. 6. Diagnosed with a stroke. 7. Diagnosed with a disease affecting muscle strength, such as Duchenne muscular dystrophy. 8. Unable to walk independently. 9. Hospitalized within 6 months prior to participation in the study. 10. Individuals contraindicated for assessment using bioelectrical impedance analysis: have a cardiac pacemaker, have open wounds, and have undergone surgery involving the implantation of metal devices in any part of the body.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary titin level at visit ELISA (pmol/mg Cr) ,Quadriceps muscle strength at visit Hand held dynamometer (kg),Hand grip strength at visit Hand grip dynamometer (kg),Rectus femoris cross-sectional area at vit Ultrasound ,Diaphragm thickness at visit Ultrasound,Parasternal intercostal muscle thickness at visit Ultrasound,Maximal inspiratory pressure at visit Pulmonary function test,Maximal expiratory pressure at visit Ultrasound,Whole body muscle mass at visit bioelectrical impedance analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| 6-minute walk test at visit 6 minute walk distance,Quality of life at visit COPD assessment test and Clinical COPD questionnaire ,Dyspnea assessment at visit modified Medical Research Council,Physical activity questionnaire at visit International Physical Activity Questionnaire Short Form | — |
Countries
Thailand
Contacts
Public ContactPimpawee Kirdsup
Department of Physiology
Outcome results
None listed